2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3917 Conserved and context-specific programs of C-MAF-directed activation in t(14;16) multiple myeloma

Sophia Chaudhry, PhD, Samantha J Lamantia, MS2, Wenjie Sun, PhD3, Derek H. Janssens, PhD4, Tim Triche Jr, PhD5
1 Van Andel Institute, 333 Bostwick Ave NE, Michigan, United States
2 Van Andel Institute, 333 Bostwick Ave NE, Michigan, United States
3 Van Andel Institute, 333 Bostwick Ave NE, Michigan, United States
4 Van Andel Institute, 333 Bostwick Ave NE, Michigan, United States
5 Van Andel Institute, 333 Bostwick Ave NE, Michigan, United States

DNA-binding transcription factors are overexpressed in numerous hematological malignancies, but how they contribute to oncogenic transformation and whether these proteins are acting in a conserved or context-specific manner that may contribute to tumor heterogeneity remains unclear. The t(14;16)(q32;q23) translocation in multiple myeloma (MM) juxtaposes the IGH promoter to the c-MAF gene, yielding constitutive overexpression. Previous c-MAF profiling studies were applied to models with additional genomic alterations such as MYC rearrangements. It is unclear how c-MAF directs oncogenic gene regulatory changes and which of these alterations may depend on interactions with the commonly amplified cofactor MYC. Therefore, we compared c-MAF occupancy across cell line models with t(14;16)(q32;q23) translocations alone, or in combination with MYC amplification. We identified c-MAF targets expressed in normal plasma cells, as well as context-specific programs of c-MAF activation that suggest a potential role in promoting MM remodeling of the bone-marrow microenvironment.

CUT&Tag was used to profile c-MAF, H3K4me2, H3K4me3, and H3K27me3 in ANBL6 cells, a t(14;16) model with no secondary MYC rearrangements. For comparison, c-MAF ChIP-seq profiles from MM.1S and JJN3 (14;16/c-MAF + 8;14/MYC) were obtained from public datasets. ANBL6 c-MAF peaks that were found in all three models were classified as core-conserved. We also identified c-MAF peak sets shared by ANBL6 and MM.1S, ANBL6 and JJN3, or specific to ANBL6.

Among the 11,481 ANBL6 c-MAF peaks, 3,059 (26.6%) were core-conserved, 1,236 (10.8%) were MM.1S-shared, 1,365 (11.9%) were JJN3-shared, and 5,821 (50.7%) were ANBL6-specific, demonstrating that approximately half of ANBL6 c-MAF occupancy was model-restricted. These core-conserved sites overlapped with active chromatin features marked by H3K4me2 more frequently than ANBL6-specific sites (54.2% vs. 29.1%, p<0.001) while core-conserved sites overlapped with active promoters marked by H3K4me3 less frequently than ANBL6-specific sites (34.8% vs. 44.5%, p<0.001). In addition, core-conserved sites overlapped with repressed chromatin features marked by H3K27me3 less frequently than ANBL6-specific sites (3.8% versus 17.7%, p<0.001). Motif enrichment distinguished the four peak classes.  Core-conserved sites contained c-MAF/bZIP recognition sequences and RUNX1, IRF4, and BACH2 family motifs, whereas ANBL6-specific sites were enriched for candidate motifs IRF/ISRE, STAT, SMAD, and IKZF. Together, this indicates the context-specific cMAF binding sites are enriched over promoters and regions of repressive chromatin and may be directed through interactions with immune regulatory proteins.

We next compared the ANBL6 c-MAF peaks to the chromatin landscape of normal plasma cell states. Among the 305 high-confidence genes associated with c-MAF and H3K4me3 co-occupancy, 223 (73.1%) are already active in healthy plasma cells, consistent with c-MAF reinforcing established plasma-cell transcriptional programming. However, we identified a smaller candidate program of 23 genes (7.5%) repressed in healthy plasma cells, indicating c-MAF is involved in promoting ectopic activation of these genes in MM cells. We confirmed the expression of 14/23 of these genes by RNA-seq expression analysis. This group of c-MAF-activated targets include the perivascular-associated genes RGS5, FGF2, and ALDH1L1, and DKK1, and the inflammatory regulators CLEC7A and STAT4.

Here, we define a conserved set of c-MAF-activated sites in t(14;16) MM and reveal context-specific roles of c-MAF that may contribute to oncogenic transformation and tumor heterogeneity. The core-conserved regions indicate that c-MAF reinforces established plasma cell programming, and that the context-specific sites that c-MAF binds, independently of MYC amplification, are associated with activation of a smaller niche-associated, perivascular, and inflammatory program. This candidate program indicates that c-MAF potentially reprograms the bone-marrow microenvironment to be more advantageous for plasma cell survival, providing a new avenue for targeting c-MAF-driven MM in the future.

Sophia Chaudhry, PhD: No relevant conflicts of interest to declare.